Related by context. Frequent words. (Click for all words.) 58 TNF blocking 57 talactoferrin 56 Pirfenidone 56 Orphan Drug status 55 heavily pretreated 55 KNS # 55 LymphoStat B 55 Nimotuzumab 55 multiple sclerosis rheumatoid arthritis 54 Ganite 54 deforolimus 54 plus prednisone 54 elotuzumab 54 6R BH4 54 NEUMUNE 53 Secondary endpoints include 53 CR# vcMMAE 53 isavuconazole 53 calcineurin inhibitors 53 ZADAXIN 53 placebo controlled clinical trials 53 MGCD# MGCD# [002] 53 ponatinib 53 hematologic cancers 52 Phenoptin 52 Phase IIa clinical trials 52 iclaprim 52 ANY WAY WITHOUT 52 ELND# 52 Azixa 52 efficacy endpoints 52 TELCYTA 52 THE EXPRESSED WRITTEN CONSENT 52 MOZOBIL 51 By Thomas Gryta 51 therapeutic regimens 51 THE REPORTING 51 RGB # 51 Phase Ib 51 CONTAINS FORWARD LOOKING STATEMENTS 51 Asentar 51 romidepsin 51 compute FFO 51 secondary efficacy endpoints 51 tanespimycin 51 Secondary endpoints 51 Secondary endpoints included 51 ocrelizumab 51 WHICH ARE NOT PURELY 51 SAFE HARBOR PROVISIONS OF 51 registrational 51 patients evaluable 51 European Medicines Evaluation 51 dose limiting toxicities 50 Juniper Networks logo 50 HIV associated lipodystrophy 50 OF THE SUBSTANCE 50 unresectable 50 NOT REPRESENT ACTUAL TRADING 50 phase IIa 50 PXD# 50 squalamine 50 SECTION #A OF 50 morbidity mortality 50 achieved statistical significance 50 AZX# 50 Carfilzomib 50 FINANCIAL CONDITION AND 50 blinded placebo controlled 50 FUSILEV 49 pharmacokinetic studies 49 OXi# 49 administered subcutaneously 49 SECTION #E OF 49 GLPG# 49 WITHIN THE MEANING OF 49 ITS REGULATION SERVICES PROVIDER 49 IIa clinical trial 49 i g 49 evaluable 49 dacarbazine 49 Serdaxin 49 ANY OF ITS AFFILIATES 49 BrachySil 49 LIMITATION MAY NOT APPLY 48 Satraplatin 48 Phase 2a trial 48 AFFILIATES AGENTS AND LICENSORS 48 IS DEFINED IN 48 Phase IIa trial 48 AVN# [001] 48 vinorelbine 48 Neuradiab 48 CA4P 48 valopicitabine 48 System Server Shutdown 48 ENTER OR USE 48 -leukemias 48 Epidemiological studies 48 ProLindac 48 Rhucin ®